Levels of 15-HETE and TXB2 in exhaled breath condensates as markers for diagnosis of childhood asthma and its therapeutic outcome

Li Chen Chen, Hsu Min Tseng, Ming Ling Kuo, Chih Yung Chiu, Sui Ling Liao, Kuan Wen Su, Ming Han Tsai, Man Chin Hua, Shen Hao Lai, Tsung Chieh Yao, Kuo Wei Yeh, Ai Hsuan Wu, Hsiu Yueh Yu, Jing Long Huang*, Shau Ku Huang*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

4 Scopus citations


Background: Dysregulation of eicosanoids is associated with asthma and a composite of oxylipins, including exhaled leukotriene B4 (LTB4), characterizes childhood asthma. While fractional exhaled nitric oxide (FeNO) has been used as the standard for monitoring steroid responsiveness, the potential utility of eicosanoids in monitoring the therapeutic outcomes remains unclear. We aimed to examine the levels of major eicosanoids representing different metabolic pathways in exhaled breath condensates (EBCs) of children with asthma during exacerbation and after treatment. Methods: Levels of 6 exhaled eicosanoid species in asthmatic children and healthy subjects were evaluated using ELISA. Results: In addition to those previously reported, including LTB4, the levels of exhaled 15-hydroxyeicosatetraenoic acid (15-HETE), but not thromboxane B2 (TXB2), showed significant difference between asthmatics (N = 318) and healthy controls (N = 97), particularly the severe group showed the lowest levels of exhaled 15-HETE. Receiver operating characteristic (ROC) curve analyses revealed similar distinguishing power for the levels of 15-HETE, FEV1 (forced expiratory volume in the first second), and FeNO, while the 15-HETE/LTB4 ratio was significantly lower in subjects with asthma as compared to that of healthy controls (p < 0.0001). Analysis of asthmatics (N = 75) during exacerbation and convalescence showed significant improvement in lung function (FEV1, p <.001), but not FeNO, concomitant with significantly increased levels of 15-HETE (p <.001) and reduced levels of TXB2 (p <.05) at convalescence, particularly for those who at the top 30% level during exacerbation. Further, decreased LTB4 and lipoxin A4 (LXA4) at convalescence were noted only in those at the top 30 percentile during exacerbation. Conclusion: The exhaled 15-HETE was found to discriminate childhood asthma while decreased levels of exhaled TXB2 and increased levels of 15-HETE were prominent at convalescence.

Original languageEnglish
Pages (from-to)1673-1680
Number of pages8
JournalPediatric Allergy and Immunology
Issue number8
StatePublished - 11 2021

Bibliographical note

Publisher Copyright:
© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.


  • 15-HETE
  • TXB
  • childhood asthma
  • exhaled breath condensates


Dive into the research topics of 'Levels of 15-HETE and TXB2 in exhaled breath condensates as markers for diagnosis of childhood asthma and its therapeutic outcome'. Together they form a unique fingerprint.

Cite this